Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM0KJDY)

• Drug Name: LY2801653 Drug Info
• Synonyms: Merestinib; LY2801653; 1206799-15-6; LY-2801653; UNII-5OGS5K699E; N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; 5OGS5K699E; N-(3-Fluoro-4-{[1-Methyl-6-(1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]oxy}phenyl)-1-(4-Fluorophenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide; C30H22F2N6O3; Merestinib [USAN]; SCHEMBL679002; LY2801653 (Merestinib); GTPL9841; CHEMBL3545307; QCR-139; DTXSID20659635; SYN1222; QHADVLVFMKEIIP-UHFFFAOYSA-N

Indication

Disease Entry	ICD 11	Status	REF
Biliary tract cancer	2C17	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 44603533
  CAS Number: CAS 1206799-15-6
  TTD Drug ID: DM0KJDY

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Protein kinase (PK)	TTU8W4S	NOUNIPROTAC	Inhibitor	[1]
Proto-oncogene c-Met (MET)	TTNDSF4	MET_HUMAN	Modulator	[3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Proto-oncogene c-Met (MET)	DTT	MET	6.737	6.293	7.744	6.879

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

• The Studied Disease: Biliary tract cancer
• ICD Disease Classification: 2C17

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Proto-oncogene c-Met (MET)	DTT	MET	1.08E-03	-0.24	-0.4

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT01285037) A Study of LY2801653 in Advanced Cancer. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of Eli Lilly.